Changchun Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Changchun Wu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Jian Huang
School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
5 shared publications - Hao Lin
School of Life Science and Technology and Center for Informational Biology, University of Electronic Science and Technology of China, Chengdu 610054, China
3 shared publications - Xueqin Xie
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Life Science and Technology University of Electronic Science and Technology of China Chengdu China
3 shared publications - Bangrong Cao
Sichuan Key Laboratory of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China , Chengdu 610041
2 shared publications - Dan Yan
Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
2 shared publications - Dongsheng Wang
Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China
2 shared publications
Latest Publications
- 1 September 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (12) , 3609-3623
Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes
- 1 September 2026
- Published by Springer Nature in Diabetologia
- Vol. 69 (12) , 3609-3623
Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes
- 31 July 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27
Transcriptomic Profiling Identifies MyD88 and Pik3r3 as Hub Genes Associated with the Anti-hypertrophic Effects of B-type Natriuretic Peptide
Introduction: B-type natriuretic peptide (BNP) is widely used to diagnose and assess heart failure prognosis. However, its effects on pathological cardiomyocyte hypertrophy and the underlying mechanisms remain largely unexplored. Methods: Here, we report the use of isoproterenol (ISO)-induced cardiomyocyte hypertrophy models with varying doses of BNP to investigate the potential targets and molecular mechanisms of BNP in rat cardiomyocyte hypertrophy. Results: Phenotypic measurement confirmed that BNP treatment significantly attenuated ISOinduced cardiomyocyte hypertrophy. Transcriptomic profiling of cardiomyocytes identified key markers and pathways associated with hypertrophy and BNP intervention, revealing that BNP could broadly reverse ISO-induced molecular perturbations. Trajectory analysis and network module analysis further highlighted MyD88 and Pik3r3 as candidate regulatory nodes associated with BNP intervention. BNP treatment potentially downregulates these genes, which is accompanied by reduced activity of inflammatory and growth-related signaling networks. These changes are associated with pathways involved in sarcomeric protein synthesis, immune-inflammatory responses, myocardial fibrosis, mitochondrial homeostasis, and oxidative stress, suggesting a potential role for BNP in attenuating cardiomyocyte hypertrophy. Discussion: These findings suggest that BNP may exert protective effects against cardiomyocyte hypertrophy through coordinated modulation of multiple signaling pathways. MyD88- and Pik3r3- associated networks emerged as potential molecular mechanisms underlying BNP-mediated responses and may represent promising targets for future investigation. Conclusion: This study provides transcriptomic evidence that BNP may attenuate cardiomyocyte hypertrophy and identifies MyD88- and Pik3r3-associated signaling networks as potential molecular mediators of this response. These findings suggest possible mechanisms underlying the protective effects of BNP and provide a foundation for future functional validation studies in hypertrophic heart disease.
- 31 July 2026
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 27
Transcriptomic Profiling Identifies MyD88 and Pik3r3 as Hub Genes Associated with the Anti-hypertrophic Effects of B-type Natriuretic Peptide
Introduction: B-type natriuretic peptide (BNP) is widely used to diagnose and assess heart failure prognosis. However, its effects on pathological cardiomyocyte hypertrophy and the underlying mechanisms remain largely unexplored. Methods: Here, we report the use of isoproterenol (ISO)-induced cardiomyocyte hypertrophy models with varying doses of BNP to investigate the potential targets and molecular mechanisms of BNP in rat cardiomyocyte hypertrophy. Results: Phenotypic measurement confirmed that BNP treatment significantly attenuated ISOinduced cardiomyocyte hypertrophy. Transcriptomic profiling of cardiomyocytes identified key markers and pathways associated with hypertrophy and BNP intervention, revealing that BNP could broadly reverse ISO-induced molecular perturbations. Trajectory analysis and network module analysis further highlighted MyD88 and Pik3r3 as candidate regulatory nodes associated with BNP intervention. BNP treatment potentially downregulates these genes, which is accompanied by reduced activity of inflammatory and growth-related signaling networks. These changes are associated with pathways involved in sarcomeric protein synthesis, immune-inflammatory responses, myocardial fibrosis, mitochondrial homeostasis, and oxidative stress, suggesting a potential role for BNP in attenuating cardiomyocyte hypertrophy. Discussion: These findings suggest that BNP may exert protective effects against cardiomyocyte hypertrophy through coordinated modulation of multiple signaling pathways. MyD88- and Pik3r3- associated networks emerged as potential molecular mechanisms underlying BNP-mediated responses and may represent promising targets for future investigation. Conclusion: This study provides transcriptomic evidence that BNP may attenuate cardiomyocyte hypertrophy and identifies MyD88- and Pik3r3-associated signaling networks as potential molecular mediators of this response. These findings suggest possible mechanisms underlying the protective effects of BNP and provide a foundation for future functional validation studies in hypertrophic heart disease.
- Open Access
- 9 September 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (12)
Enhancing polyreactivity prediction of preclinical antibodies through fine-tuned protein language models
- 9 September 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (12)
Open AccessEnhancing polyreactivity prediction of preclinical antibodies through fine-tuned protein language models
- Open Access
scRiskCell: A single‐cell framework for quantifying islet risk cells and their adaptive dynamics in type 2 diabetes
ScRiskCell is an interpretable intelligent computational framework that leverages nearly 500,000 islet cell expression profiles from 106 donors across different continuous disease states. By calculating the intrinsic relationship between donor disease states and cell expression profiles, it assigns a pseudo‐cell state index to each cell. Sorting the pseudo‐indexes of cells enables the identification of risk cells truly disrupted by the disease. Importantly, scRiskCell reveals the dynamic aggregation pattern of risk cells during disease progression, providing mechanistic insights for early disease prediction and clinical dynamic monitoring of disease progression.
Open AccessscRiskCell: A single‐cell framework for quantifying islet risk cells and their adaptive dynamics in type 2 diabetes
ScRiskCell is an interpretable intelligent computational framework that leverages nearly 500,000 islet cell expression profiles from 106 donors across different continuous disease states. By calculating the intrinsic relationship between donor disease states and cell expression profiles, it assigns a pseudo‐cell state index to each cell. Sorting the pseudo‐indexes of cells enables the identification of risk cells truly disrupted by the disease. Importantly, scRiskCell reveals the dynamic aggregation pattern of risk cells during disease progression, providing mechanistic insights for early disease prediction and clinical dynamic monitoring of disease progression.
- Open Access
- 12 April 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
PlateletBase: A Comprehensive Knowledgebase for Platelet Research and Disease Insights
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA sequencing (RNA-seq) data from 3711 samples across 41 different conditions available on the National Center for Biotechnology Information (NCBI). PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4869 proteomic entries, 2614 omics knowledge entries, 1833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. The case studies on gray platelet syndrome and angina pectoris demonstrate that PlateletBase is a suitable tool for identifying diagnostic biomarkers and exploring disease mechanisms, thereby advancing research in platelet functionality. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/.
- 12 April 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 23 (2)
Open AccessPlateletBase: A Comprehensive Knowledgebase for Platelet Research and Disease Insights
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA sequencing (RNA-seq) data from 3711 samples across 41 different conditions available on the National Center for Biotechnology Information (NCBI). PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4869 proteomic entries, 2614 omics knowledge entries, 1833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. The case studies on gray platelet syndrome and angina pectoris demonstrate that PlateletBase is a suitable tool for identifying diagnostic biomarkers and exploring disease mechanisms, thereby advancing research in platelet functionality. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/.
- Open Access
PlateletBase: A Comprehensive Knowledgebase for Platelet Research and Disease Insights
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA-seq data from 3,711 samples across 41 different conditions available on NCBI. PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4,869 proteomic entries, 2,614 omics knowledge entries, 1,833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. Case study results, such as those from gray platelet syndrome and angina pectoris, demonstrate that this tool can aid in identifying diagnostic biomarkers and exploring disease mechanisms, significantly advancing research in platelet functionality and its applications. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/ .
Open AccessPlateletBase: A Comprehensive Knowledgebase for Platelet Research and Disease Insights
Platelets are vital in many pathophysiological processes, yet there is a lack of a comprehensive resource dedicated specifically to platelet research. To fill this gap, we have developed PlateletBase, a knowledge base aimed at enhancing the understanding and study of platelets and related diseases. Our team retrieved information from various public databases, specifically extracting and analyzing RNA-seq data from 3,711 samples across 41 different conditions available on NCBI. PlateletBase offers six analytical and visualization tools, enabling users to perform gene similarity analysis, pair correlation, multi-correlation, expression ranking, clinical information association, and gene annotation for platelets. The current version of PlateletBase includes 10,278 genomic entries, 31,758 transcriptomic entries, 4,869 proteomic entries, 2,614 omics knowledge entries, 1,833 drugs, 97 platelet resources, 438 diseases/traits, and six analysis modules. Each entry has been carefully curated and supported by experimental evidence. Additionally, PlateletBase features a user-friendly interface designed for efficient querying, manipulation, browsing, visualization, and analysis of detailed platelet protein and gene information. Case study results, such as those from gray platelet syndrome and angina pectoris, demonstrate that this tool can aid in identifying diagnostic biomarkers and exploring disease mechanisms, significantly advancing research in platelet functionality and its applications. PlateletBase is accessible at http://plateletbase.clinlabomics.org.cn/ .